Investigation of heavy metal effects on immobilized paraoxanase by glutaraldehyde

References

• Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673–1684.
   PubMedGoogle Scholar
• Polat MF, Nalbantoğlu B. In vitro esterase activity of carbonic anhydrase on total esterase activity level in serum. Turk J Med Sci 2002;32:299–302.
   Google Scholar
• Basaran I, Sinan S, Cakir U, Bulut M, Arslan O, Ozensoy O. In vitro inhibition of cytosolic carbonic anhydrases I and II by some new dihydroxycoumarin compounds. J Enzym Inhib Med Chem 2007;23:1,32–36.
   Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Pat 2006;16:1627–1644.
   Web of Science ®Google Scholar
• Agrawal S, Tripathi G, Prajnya R, Sinha N, Gilmour A, Bush L et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009;63:335–344.
   PubMedGoogle Scholar
• Turk R, Juretic D, Geres D, Turk N, Rekic B, Simeon-Rudolf V et al. Serum paraoxonase activity and lipid parameters in the early postpartum period of dairy cows. Res Vet Sci 2004;76:57–61.
   PubMedGoogle Scholar
• Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 1995;92:7187–7191.
   PubMed Web of Science ®Google Scholar
• Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100–106.
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: a new role for RU-486 and related compounds. J Clin Invest 1994;94:1990–1995.
   PubMed Web of Science ®Google Scholar
• Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. Belgium: Center for Experimental Surgery and Anesthesiology, Katholieke Universiteit Leuven.
   Google Scholar
• Rodrigo L, Gil F, Hernández AF, Pla A. Identification of two rat liver proteins with paraoxonase activity: biochemical evidence for the identity of paraoxonase and arylesterase. Chem Biol Interact 1999;119-120:263–275.
   PubMedGoogle Scholar
• Selek S, Cosar N, Kocyigit A, Erel O, Aksoy N, Gencer M et al. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clin Biochem 2008;41:140–144.
   PubMed Web of Science ®Google Scholar
• Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genom 1996;33:498–507.
   PubMed Web of Science ®Google Scholar
• Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004;37:1317–1323.
   PubMed Web of Science ®Google Scholar
• Karakaya A, Ibis S, Kural T, Köse SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 1999;118:193–200.
   PubMedGoogle Scholar
• Akçay YD, Sagin FG, Sendag F, Oztekin K, Sozmen EY. Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: does paraoxonase genotype play a role? Maturitas 2006;53:325–332.
   PubMedGoogle Scholar
• Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G et al. Responsiveness to cholinesterase inhibitors in Alzheimer’s disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005;382:338–341.
   PubMed Web of Science ®Google Scholar
• Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009;235:1–9.
   PubMed Web of Science ®Google Scholar
• Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541–550.
   PubMed Web of Science ®Google Scholar
• Alici HA, Ekinci D, Beydemir S. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin Biochem 2008;41:1384–1390.
   PubMed Web of Science ®Google Scholar
• Ikedaa Y, Suehiroa T, Ariia K, Kumonb Y, Hashimotoa K. High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism 2008;57:1725–1732.
   PubMedGoogle Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscl Throm Vas 2001;21:473–480.
   Google Scholar
• Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49–55.
   PubMed Web of Science ®Google Scholar
• Efrat M, Aviram M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 2008;376:105–110.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 2008;44:1951–1959.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Prasad P, B K T, Kumar KM, Ammini AC, Gupta A et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes. J Diabetes Complicat 2009;23:102–111.
   PubMed Web of Science ®Google Scholar
• Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson’s disease in a Finnish population. Neurosci Lett 2004;367:168–170.
   PubMed Web of Science ®Google Scholar
• Jakoby WB. Crystallization as a purification technique. In: Jakoby, WB. (ed.), Enzyme Purification and Related Techniques Method Enzymol 1971;Vol. 22, New York: Academic Press.
   Google Scholar
• Arslan O, Beyaztaş S, Sinan S. Inhibition of plant growth regulators on paraoxonase activity. FEB 2008;17:1994–1999.
   Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565–574.
   PubMed Web of Science ®Google Scholar
• Builder SE. Hydrophobic interaction chromatography, principles and methods. San Francisco: Amersham Pharmacia Biotech, So; 1993.
   Google Scholar
• Warren BS, Kusk P, Wolford RG, Hager GL. Purification and stabilization of transcriptionally active glucocorticoid receptor. J Biol Chem 1996;271:11434–11440.
   PubMedGoogle Scholar
• Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006;187:74–81.
   PubMed Web of Science ®Google Scholar
• Munson PJ, Rodbard D. An exact correction to the “Cheng-Prusoff” correction. J Recept Res 1988;8:533–546.
   PubMed Web of Science ®Google Scholar
• Huang X. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 2003;8:34–38.
   PubMed Web of Science ®Google Scholar
• Habeeb AJ, Hiramoto R. Reaction of proteins with glutaraldehyde. Arch Biochem Biophys 1968;126:16–26.
   PubMed Web of Science ®Google Scholar
• Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. BioTechniques 2004;37:790–6, 798.
   PubMedGoogle Scholar
• Ahmed SA, Saleh SA, Abdel-Fattah AF. Stabilization of Bacillus licheniformis ATCC 21415 alkaline protease by immobilization and modification. Australian J Basic Appl Sci 2007;1:313–322.
   Google Scholar
• Pellin MC, Moretto A, Lotti M, Vilanova E. Distribution and some biochemical properties of rat paraoxonase activity. Neurotoxicol Teratol 1990;12:611–614.
   PubMed Web of Science ®Google Scholar
• Debord J, Dantoine T, Bollinger JC, Abraham MH, Verneuil B, Merle L. Inhibition of aryesterase by aliphatic alcohols. Chem-Biol Interact 1998;113:105–115.
   PubMedGoogle Scholar
• Debord J, Bollinger JC, Merle L, Dantoine T. Inhibition of human serum arylesterase by metal chlorides. J Inorg Biochem 2003;94:1–4.
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol Trace Elem Res 2010;135:112–120.
   PubMed Web of Science ®Google Scholar